CALGARY, ALBERTA--(Marketwired - Mar 14, 2014) - Supreme Pharmaceuticals Inc. ("Supreme" or the "Corporation") (TSX-VENTURE:SL)(OTCBB:SPRWF), formerly Supreme Resources Ltd., announces that it has changed its name to Supreme Pharmaceuticals Inc. in conjunction with its recent decision to pursue interests in pharmaceuticals and biomedical devices. The TSX Venture Exchange has advised the Corporation that trading under the new name and symbol "SL" will commence on March 14, 2014.

David Stadnyk, President & CEO, stated, "Although there is no certainty that a transaction will be successfully concluded, the Corporation is in negotiations to acquire an exclusive license agreement from an independent third party, providing for the commercialization of patented technology focused on treating gastrointestinal diseases and disorders. We are excited about diversifying Supreme's focus to include multiple bio-technologies, with an initial focus on obesity. The global obesity market is valued at over $1.6 trillion and the Corporation hopes to make an announcement with regards to its continued negotiations soon."

About Supreme Pharmaceuticals Inc.

Supreme Pharmaceuticals Inc., formerly Supreme Resources Ltd., holds advanced base and precious metals projects located in producing mining districts of British Columbia, Canada. It has recently taken the strategic decision to acquire business interests in the life sciences field in order to increase shareholder value.

Website: www.supremepharmaceuticals.com.

Further news will be forthcoming in the near future.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States.

Supreme Pharmaceuticals Inc.David StadnykPresident & CEO403-210-8350info@supremepharmaceuticals.comwww.supremepharmaceuticals.com